



Multiple Sclerosis Research Australia Limited

ACN 008 581 431

Annual Financial Report for the Year Ended 30 June 2019

(Abridged version)

Multiple Sclerosis Research Australia Limited

	Page Number
<i>Future Agreements for Research</i>	2
<i>Statement of Comprehensive Income</i>	3
<i>Statement of Financial Position</i>	4
<i>Statement of Changes in Equity</i>	5
<i>Statement of Cash Flows</i>	6
<i>Additional informa furnished under the Charitable Fundraising Act (NSW) 1991</i>	7

Multiple Sclerosis Research Australia Limited

Future Agreements for Research (Cont'd)

	30 June 2019	30 June 2018
	\$	\$
RMC, Platform & Other projects		
RMC projects		
Fellowships and Scholarships	831,305	1,337,428
Investigator Driven Projects	1,943,065	1,573,417
Total RMC projects	2,774,370	2,910,845
Platform projects		
MS Life Study/Longitudinal Study	776,347	105,703
Prevention Study	1,088,021	1,543,768
NSW Clinical Trials Network #1	-	-
ARC Linkage	-	19,478
ANZGene #1	-	23,747
MS Brain Bank #1	-	-
Total Platform projects	1,864,368	1,692,696
Other projects		
International Progressive MS Alliance	396,962	879,861
Queensland Institute of Medical Research Project #2	-	56,898
Total other projects	396,962	936,759
Total Future Agreements as at June	5,035,700	5,540,300

#1 Platform projects continue with internal expenditure.

#2 The joint agreement between MS Research Australia, MS Society of Queensland and Queensland Institute of Medical Research ended in September 2018.

The above table illustrates future multi-years research commitments by Multiple Sclerosis Research Australia Limited as at end of each financial year.

Declaration of Directors Interests

Directors have from time to time made non-specific donations to the company.

The Company receives grants from most MS state based organisations. During the financial year, two former Directors, Dr Annette Carruthers (resigned: 24 November 2018) and Mr Paul Murnane (resigned: 16 February 2019) were also former Directors of Multiple Sclerosis Australia.

During the financial year, the appointment of Assoc. Professor Desmond Graham and Mr Ron Brent are also directors of Multiple Sclerosis Australia and Multiple Sclerosis Limited.

Organisations that are associated with Professor Graeme Stewart AM, Professor Helmut Butzkueven and Assoc. Professor Desmond Graham have no financial interest, may have received research grants. They are not a member of the Research Management Council (RMC) and did not participate in the grant approval process through the RMC when these grants were assessed and approved.

Multiple Sclerosis Research Australia Limited

Statement of Comprehensive Income for the year ended 30 June 2019

	Notes	2019 \$	2018 (Restated) \$
Gross Revenue			
Donations & Fundraising		2,278,685	2,368,186
Gifts in Will		389,000	332,183
Kiss Goodbye to MS (include The May 50K fundraising campaign)		2,760,257	810,670
Sponsorships (including pharmaceutical companies)		20,000	359,778
Government Grants		355,000	276,250
Contributions from State based MS organisations and Multiple Sclerosis Australia	24(b)	719,899	2,235,595
Dividend received		16,677	42,814
Interest revenue		205,978	164,016
Total Revenue		6,745,496	6,589,492
Expenditure			
Administration expenditure	2(b)	(916,954)	(714,255)
Kiss Goodbye to MS campaign	2(c)	(664,538)	(314,523)
Other Fundraising Expenditure	2(d)	(649,517)	(468,635)
Research and Strategic Expenditure			
Grants for Research		(1,910,923)	(1,628,856)
Other Research Expenditure	2(e)	(1,724,161)	(2,202,015)
Research and Strategic Expenditure	2(f)	(951,884)	(963,121)
Total Expenditure		(6,817,977)	(6,291,405)
(Deficit)/Income before investment transactions		(72,481)	298,087
Net fair value gain/(loss) on financial assets at fair value through profit or loss	23	8,118	(3,792)
(Deficit)/Income before Income tax expense		(64,363)	294,295
Income tax expense	1(a)	-	-
(Deficit)/Income Attributable to Members of the Entity		(64,363)	294,295
Total comprehensive (deficit)/income for the year		(64,363)	294,295

The above statement of comprehensive income should be read in conjunction with the accompanying notes.

Multiple Sclerosis Research Australia Limited

Statement of Financial Position as at 30 June 2019

	Notes	2019 \$	2018 (Restated) \$
ASSETS			
Current assets			
Cash and cash equivalents	14(a)	2,060,845	1,685,083
Short term investments	15	8,479,221	6,840,362
Trade and other receivables	5	79,062	1,882,553
Prepayment and other assets	5	249,501	129,878
Total current assets		10,868,629	10,537,876
Non current assets			
Plant and equipment	6	21,012	11,094
Intangibles	7	21,766	66,504
Other financial assets	8	339,640	331,522
Total non current assets		382,418	409,120
Total assets		11,251,047	10,946,996
LIABILITIES			
Current liabilities			
Trade and other payables	9	685,445	257,837
Income received in advance	10	289,325	355,784
Annual leave payable	16	58,668	56,716
Provision for long service leave	17	21,252	17,254
Total current liabilities		1,054,690	687,591
Non current liability			
Provision for long service leave	17	57,697	56,382
Total non current liability		57,697	56,382
Total liabilities		1,112,387	743,973
Net Assets		10,138,660	10,203,023
Total Members' Funds			
Contributed equity		3,272,730	3,272,730
Retained earnings	11	6,865,930	6,930,293
		10,138,660	10,203,023

The above statement of financial position should be read in conjunction with the accompanying notes.

Multiple Sclerosis Research Australia Limited

Statement of Changes in Equity for the Year Ended 30 June 2019

	Retained Earnings \$	Contributed Equity \$	Total \$
Balance as at 1 July 2017 (Restated)	6,635,998	3,272,730	9,908,728
Total comprehensive income for the year	294,295	-	294,295
Balance as at 30 June 2018 (Restated)	6,930,293	3,272,730	10,203,023
Total comprehensive (deficit) for the year	(64,363)	-	(64,363)
Balance as at 30 June 2019	6,865,930	3,272,730	10,138,660

The above statement changes in equity should be read in conjunction with the accompanying notes.

Multiple Sclerosis Research Australia Limited

Statement of Cash Flows for the Year Ended 30 June 2019

	2019	2018
Note	\$	\$
Cash Flows From Operating Activities		
Cash receipts in course of operations	6,430,533	6,410,329
Cash payments in course of operations	(4,611,267)	(5,993,889)
Net cash provided by operating activities	14(b) <u>1,819,266</u>	416,440
Cash Flows from Investing Activities		
(Purchase)/Disposal of plant and equipment	(19,734)	4,699
(Purchase) of intangibles	-	(5,091)
Disposal of financial instruments	1(l) -	716,804
Net (renew) of term deposits	(1,638,859)	(2,987,189)
Interest/Dividend income received	222,655	206,830
Net cash from/(used) in investing activities	14(c) <u>(1,435,938)</u>	(2,063,947)
Cash Flows from Financing Activities		
Interest paid	(7,566)	-
Net cash used in financing activities	(7,566)	-
Net (decrease)/increase in cash and cash management	375,762	(1,647,507)
Cash and cash equivalents at beginning of the financial year	1,685,083	3,332,590
Cash and cash equivalents at end of the financial year	14(a) <u>2,060,845</u>	<u>1,685,083</u>

The above statement of cash flows should be read in conjunction with the accompanying notes.

Multiple Sclerosis Research Australia Limited

Additional Information furnished under the Charitable Fundraising Act 1991 (NSW), Fundraising Act 1998 (VIC), Collections Act 1966 (QLD) and Collections for Charities Act 2001 (TAS).

	Year to 30 June 2019			Year to 30 June 2018		
	Gross revenue	Direct Expense	Net Proceeds	Gross revenue	Direct Expense	Net Proceeds
Fundraising and donations	2,278,685	649,517	1,629,168	2,368,186	468,635	1,899,551
Gifts in Will	389,000	-	389,000	332,183	-	332,183
Kiss Goodbye to MS	2,760,257	664,538	2,095,719	810,670	314,523	496,147
Pharma Sponsorships	20,000	-	20,000	359,778	-	359,778
Government Grants	355,000	-	355,000	276,250	-	276,250
Contributions from State based MS organisations	719,899	-	719,899	2,235,595	-	2,235,595
Total	6,522,841	1,314,055	5,208,786	6,382,662	783,158	5,599,504
Administrative Expenditure			916,954			714,255
Net amount raised before Research and Strategic Expenditure			4,291,832			4,885,249
			% of Gross Revenue			% of Gross Revenue
Direct Expenditure			20%			12%
Administrative Expenditure			14%			11%
Total Expenditure			34%			23%
Net amount raised goes to funding research and strategic expenditures			66%			77%

Multiple Sclerosis Research Australia Limited

Additional Information furnished under the Charitable Fundraising Act 1991 (NSW), Fundraising Act 1998 (VIC), Collections Act 1966 (QLD) and Collections for Charities Act 2001 (TAS) (Cont'd).

1. Revenue as per Statement of Comprehensive Income

	2019	2018
	\$	\$
Total Gross Revenue	6,745,496	6,589,492
Less Interest revenue and dividend received	222,655	206,830
	6,522,841	6,382,662

2. Total Expenditure as per Statement of Comprehensive Income

Total Expenditure	6,817,977	6,291,405
Less:		
Research Grants	1,910,923	1,628,856
Other Research Expenditure (refer to Note 2 (d))	1,724,161	2,202,015
Non Fundraising Costs - Research Grants and expenditure	3,635,084	3,830,871
Less:		
Audit Fees	27,000	25,500
Multiple Sclerosis Australia services & other recharge	106,451	104,387
Management: Employee & Other Costs	783,503	584,368
Research and Strategic Administration	951,884	963,121
Non Fundraising Costs	1,868,838	1,677,376

3. Fundraising Costs as per Statement of Comprehensive Income

Other fundraising costs	649,517	468,635
Kiss Goodbye to MS	664,538	314,523
Fundraising Costs as per Statement of Comprehensive Income	1,314,055	783,158

4. Cost of Services Provided

Non Fundraising Costs Research Grants	3,635,084	3,830,871
---------------------------------------	------------------	-----------

(a) Fundraising Activities Conducted

Gross Proceeds:

Fundraising, donations and Gifts in Will	2,667,685	2,700,369
Kiss Goodbye to MS	2,760,257	810,670
Sponsorships - Pharmaceutical Companies	20,000	359,778
Government Grants	355,000	276,250
Contributions from State based MS organisations and MS Australia	719,899	2,235,595
Gross Proceeds from Fundraising Appeals	6,522,841	6,382,662

Multiple Sclerosis Research Australia Limited

Additional Information furnished under the Charitable Fundraising Act 1991 (NSW), Fundraising Act 1998 (VIC), Collections Act 1966 (QLD) and Collections for Charities Act 2001 (TAS) (Cont'd).

Comparisons of Monetary figures and percentages

	2019		2018	
	\$	%	\$	%
Total Cost of Fundraising to Gross Fundraising Income	1,314,055 / 6,522,841	20%	783,158 / 6,382,662	12%
Net Surplus from Fundraising to Gross Income from Fundraising	[6,522,841 - 1,314,055] / 6,522,841	80%	[6,382,662 - 783,158] / 6,382,662	88%
Total Cost of Services to Total Expenditure (Less Fundraising Costs)	3,635,084 / [6,817,977 - 1,314,055]	66%	3,830,871 / [6,291,405 - 783,158]	70%
Total Cost of Services to Total Income Received (Less Interest revenue & Dividend received and Fundraising expenditure)	3,635,084 / [6,522,841 - 1,314,055]	70%	3,830,871 / [6,382,662 - 783,158]	68%